Resources from the same session
445MO - Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
Presenter: Frank Giordano
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
446MO - SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
447MO - A clinical study of the safety and efficacy of anlotinib hydrochloride combined with temozolomide dose density scheme for the treatment of recurrent high grade glioma
Presenter: liang wang
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 445MO, 446MO and 447MO
Presenter: Giuseppe Lombardi
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast
448MO - A clinical study of the safety and efficacy of toripalimab in combination with anilotinib for the treatment of recurrent glioblastoma (GBM)
Presenter: liang wang
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
449MO - Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results
Presenter: Fabio Ciceri
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
450MO - Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
451MO - Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Presenter: Maria Angeles Vaz Salgado
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
452MO - Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
Presenter: Estela Pineda
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
453MO - A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast